Eddington named to Inovio advisory board
Thomas S. Eddington, Emeritus Professor of the Scripps Research Institute and founder of several biotechnology companies, has joined the advisory board of Inovio Pharmaceuticals, a company developing leader therapeutic and preventive vaccines against cancers and infectious diseases.
A La Jolla resident and graduate of Stanford University, Eddington has a broad base of experience ranging from designing the first heart lung machine to creating the Nuclear Medicine program at Scripps and building an atomic pile in his backyard at age 14.
He served in the military at the direction of the Atomic Bomb Casualty Commission in Japan discovering the chromosomal break that caused post-bomb leukemia in Hiroshima. He and his associates became the first group to clone tissue factor, which is the initiating molecule for blood coagulation, bleeding, thrombosis and sepsis pathways.